Join TherapeutAix at the SMR Meeting ‘Innovative New Pharma & Biotech Partnerships’
Darcey Black, Translational Director at TherapeutAix, will be co-organising and attending the ‘Innovative New Pharma and Biotech Partnerships: How is the landscape transforming?’ SMR Meeting taking place on 7th July 2022 at GSK Stevenage. The meeting will feature a panel; of experts from industry, CROs, medical charities and VCs who will share experiences and lessons […]
International NASH Day 2022 – Enabling therapies for patients
Non-alcoholic steatohepatitis, or NASH, remains a disease with no approved therapeutics. And it’s been a tough area for drug development, with numerous Phase 2b and Phase 3 failures in the last few years. As a result, the landscape of active development projects has changed quite a bit from the time our review on NASH was […]
TherapeutAix to present at Extracellular Matrix Pharmacology Congress
TherapeutAix is attending and presenting at the Extracellular Matrix Pharmacology Congress 2022, on 23-25 June at the Tivoli Congress Centre in Copenhagen. The congress will bring together experts from across the industry to discuss the extracellular matrix across organ diseases including liver, lung, kidney, skin, and immunology. Darcey Black (Director, Translational) will be presenting a […]
TherapeutAix to host Outsourcing Workshop at BOS Virtual 2021
Darcey Black and Simon Cruwys will be running the Outsourcing Workshop at this year’s BOS Virtual. Biotech Outsourcing Strategies is an established outsourcing focused conference and exhibition for the international Pharmaceutical industry. The event scope is focused on Discovery outsourcing and CMC outsourcing for both small molecules and biologics (primarily development stage). Darcey will be introducing the session and will explain the TherapeutAix model for collaboration […]
Christmas 2020 roundup from the TherapeutAix team
As 2020 draws to a close, the team at TheraeutAix has been looking back and reflecting on the last 12 months. Here’s a recap. A pandemic that changed a lot Let’s start with the obvious. The coronavirus pandemic challenged how we engaged with colleagues, conferences and in networking. We enjoyed our only in person meeting […]
Drug Development in IPF
Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib, need to be considered when selecting and developing new drug candidates. We discuss the challenges and opportunities in our new review in Drug Discovery Today. We probably don’t need to highlight the fact that despite […]
Alderley Analytical and Peak Proteins join the TherapeutAix Network
Following a recent collaboration, TherapeutAix is delighted to announce the addition of Alderley Analytical and Peak Proteins as network partners. TherapeutAix has joined with Alderley Analytical, which provides specialist bioanalytical services to support drug development programmes, and Peak Proteins, which offers protein expression and purification, protein crystallography, and protein mass spectrometry. The bespoke and dedicated […]
TherapeutAix turns two!
This September, TherapeutAix is two years old. Here, we look back on the past 12 months, and take a sneak peek into the future. Our Customers Our core mission is to help bring molecules with promise to life – and we are helping more customers in planning and navigating their drug discovery and development projects. […]
COVID-19 and Learning about Lung Fibrosis
Emerging understanding of the clinical course of COVID-19 may enable a better understanding of fibrosis in the lung. Future learnings may eventually be applicable to IPF and require new approaches to drug development. Reversing fibrosis and restoring lung function has been an aspiration for the treatment of patients with interstitial lung disease (ILD) but the […]
Common denominators in fibrotic lung disease
With fibrotic disease being one of our areas of interest, it has been highly interesting to follow the news in the past six months or so around nintedanib. It is one of only two approved drugs for idiopathic pulmonary fibrosis, IPF. IPF continues to be a focus area for drug development. Even though its root […]